Jimenez Relishes Prospect of EFPIA Presidency
EFPIA has announced the official appointment of Joe Jimenez, CEO of Novartis, as its new President.
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has announced the official appointment of Joe Jimenez, CEO of Novartis, as its new President. He will work alongside the new Vice Presidents, Dr. Stefan Oschmann, CEO Pharma of Merck KGaA, and Marc de Garidel, Chairman and CEO of Ipsen.
Jimenez was previously EFPIA Vice-President. He was already President-Elect at the time of former EFPIA President Chris Viehbacher’s resignation on October 29, 2014, and was due to take over leadership of EFPIA in June 2015. Jimenez’s appointment is likely to run until June 2017, but his must be ratified during the EFPIA General Assembly in June 2015.
"My vision is for a prosperous Europe in which all stakeholders are aligned towards improving and rewarding positive patient outcomes. I believe this is the right thing to do for patients, and for the sustainability of our health systems. Importantly, it will also drive sustained R&D investment and jobs in Europe,” he said.
According to Richard Bergström, Director General of EFPIA, Jimenez’s experience in the pharmaceutical industry, both within and beyond EFPIA, will prove of great value, and his dedication to cross-sector dialogue and collaboration will help EFPIA to take its Health & Growth strategy to the next level.
Launched in 2014, EFPIA’s Health & Growth strategy aims to take an innovative collaborative approach towards a stronger, healthier EU, around three pillars: health outcomes, sustainable financing, and a thriving ecosystem. As Europe emerges from the financial crisis, there is an opportunity to re-orient the way European health systems operate, moving from a focus on transactions to a paradigm centered on health outcomes for patients, Bergström believes.
“I look forward to taking on this important role and to working with my colleagues in the pharmaceutical industry, and with our stakeholders, as we shape the future of innovative medicines in Europe. With the new Commission in office, it is an exciting time as health and life sciences are central to the EU agenda,” noted Jimenez.
Read the full release here.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
